Eurosurv. Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany’s experience duri

[tetano]

• Nita Perumal[SUP]1,2[/SUP] , Viktoria Schönfeld[SUP]1,2[/SUP] , Ole Wichmann[SUP]1[/SUP]

The screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced in real-time for different age groups and clinical outcomes. Here we describe the country’s overall positive experience using the screening method, including its strengths and limitations, and provide practical guidance regarding a few issues, such as case definition stringency, testing behaviour, and data stratification, that require careful consideration during data analysis and the interpretation of the results.
​
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.29.8.2300329